Sagar U Nigwekar1, Julia Wenger, Ravi Thadhani, Ishir Bhan. 1. Division of Nephrology, Massachusetts General Hospital, Boston, MA; Scholars in Clinical Science Program, Harvard Medical School, Boston, MA. Electronic address: sagarnigs@gmail.com.
Abstract
BACKGROUND: Hyponatremia is associated with increased mortality in chronic diseases. Recent animal studies also implicate hyponatremia in bone abnormalities. However, associations between hyponatremia, mineral bone abnormalities, and mortality in incident hemodialysis patients are unknown. STUDY DESIGN: Nonconcurrent prospective cohort study. SETTING & PARTICIPANTS: Incident hemodialysis patients from the Accelerated Mortality on Renal Replacement (ArMORR) cohort with available serum sodium measurements from the time of dialysis therapy initiation (n = 6,127) were classified as hyponatremic (sodium, <135 mEq/L) or normonatremic (sodium, 135-145 mEq/L) based on glucose-corrected sodium level at the time of dialysis therapy initiation. Patients with sodium levels >145 mEq/L were excluded (n = 74). PREDICTOR: Hyponatremia (sodium, <135 mEq/L). OUTCOMES: Mineral bone abnormalities; rates of falls, fractures, and mortality. MEASUREMENTS: Hyponatremia and mineral bone abnormalities were assessed at the time of hemodialysis therapy initiation. Data for other outcomes were collected during a 1-year follow-up. Univariate and multivariable logistic and Cox proportion hazard analyses were conducted to compute ORs and HRs, respectively, with 95% CIs. RESULTS: 775 patients were hyponatremic and 5,278 were normonatremic at baseline. In univariate analyses, hyponatremia was associated with hypercalcemia (OR, 1.92; 95% CI, 1.11-3.30), elevated alkaline phosphatase level (OR, 1.36; 95% CI, 1.12-1.66), and hypoparathyroidism (OR, 1.40; 95% CI, 1.18-1.65). Similar relationships were observed in multivariable models. No statistically significant relationships were observed with phosphorus abnormalities, hypovitaminosis D, falls, or fractures. 965 (15.8%) patients had died at the 1-year follow up. Compared with normonatremic patients, hyponatremic patients had higher 1-year mortality in univariate (HR, 1.59; 95% CI, 1.34-1.87) and multivariable analyses (HR, 1.42; 95% CI, 1.19-1.69). LIMITATIONS: Low rate of falls and fractures, lack of data for bone density and fibroblast growth factor 23. CONCLUSIONS: In incident hemodialysis patients, hyponatremia is associated with hypercalcemia, elevated alkaline phosphatase levels, hypoparathyroidism, and increased 1-year mortality. Future studies are needed to examine whether treatments to alter hyponatremia have effects on mineral bone abnormalities and mortality.
BACKGROUND:Hyponatremia is associated with increased mortality in chronic diseases. Recent animal studies also implicate hyponatremia in bone abnormalities. However, associations between hyponatremia, mineral bone abnormalities, and mortality in incident hemodialysis patients are unknown. STUDY DESIGN: Nonconcurrent prospective cohort study. SETTING & PARTICIPANTS: Incident hemodialysis patients from the Accelerated Mortality on Renal Replacement (ArMORR) cohort with available serum sodium measurements from the time of dialysis therapy initiation (n = 6,127) were classified as hyponatremic (sodium, <135 mEq/L) or normonatremic (sodium, 135-145 mEq/L) based on glucose-corrected sodium level at the time of dialysis therapy initiation. Patients with sodium levels >145 mEq/L were excluded (n = 74). PREDICTOR: Hyponatremia (sodium, <135 mEq/L). OUTCOMES: Mineral bone abnormalities; rates of falls, fractures, and mortality. MEASUREMENTS: Hyponatremia and mineral bone abnormalities were assessed at the time of hemodialysis therapy initiation. Data for other outcomes were collected during a 1-year follow-up. Univariate and multivariable logistic and Cox proportion hazard analyses were conducted to compute ORs and HRs, respectively, with 95% CIs. RESULTS: 775 patients were hyponatremic and 5,278 were normonatremic at baseline. In univariate analyses, hyponatremia was associated with hypercalcemia (OR, 1.92; 95% CI, 1.11-3.30), elevated alkaline phosphatase level (OR, 1.36; 95% CI, 1.12-1.66), and hypoparathyroidism (OR, 1.40; 95% CI, 1.18-1.65). Similar relationships were observed in multivariable models. No statistically significant relationships were observed with phosphorus abnormalities, hypovitaminosis D, falls, or fractures. 965 (15.8%) patients had died at the 1-year follow up. Compared with normonatremic patients, hyponatremic patients had higher 1-year mortality in univariate (HR, 1.59; 95% CI, 1.34-1.87) and multivariable analyses (HR, 1.42; 95% CI, 1.19-1.69). LIMITATIONS: Low rate of falls and fractures, lack of data for bone density and fibroblast growth factor 23. CONCLUSIONS: In incident hemodialysis patients, hyponatremia is associated with hypercalcemia, elevated alkaline phosphatase levels, hypoparathyroidism, and increased 1-year mortality. Future studies are needed to examine whether treatments to alter hyponatremia have effects on mineral bone abnormalities and mortality.
Authors: Manfred Hecking; Angelo Karaboyas; Rajiv Saran; Ananda Sen; Walter H Hörl; Ronald L Pisoni; Bruce M Robinson; Gere Sunder-Plassmann; Friedrich K Port Journal: Am J Kidney Dis Date: 2011-09-23 Impact factor: 8.860
Authors: Louise Balling; Morten Schou; Lars Videbæk; Per Hildebrandt; Henrik Wiggers; Finn Gustafsson Journal: Eur J Heart Fail Date: 2011-07-09 Impact factor: 15.534
Authors: Luca Bettari; Mona Fiuzat; Linda K Shaw; Daniel M Wojdyla; Marco Metra; G Michael Felker; Christopher M O'Connor Journal: J Card Fail Date: 2011-10-19 Impact factor: 5.712
Authors: Christiane Drechsler; Marion Verduijn; Stefan Pilz; Raymond T Krediet; Friedo W Dekker; Christoph Wanner; Markus Ketteler; Elisabeth W Boeschoten; Vincent Brandenburg Journal: Clin J Am Soc Nephrol Date: 2011-05-19 Impact factor: 8.237
Authors: Lilia R Lukowsky; Leeka Kheifets; Onyebuchi A Arah; Allen R Nissenson; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2012-06-06 Impact factor: 3.754
Authors: E Sbardella; A M Isidori; G Arnaldi; M Arosio; C Barone; A Benso; R Berardi; G Capasso; M Caprio; F Ceccato; G Corona; S Della Casa; L De Nicola; M Faustini-Fustini; E Fiaccadori; L Gesualdo; S Gori; A Lania; G Mantovani; P Menè; G Parenti; C Pinto; R Pivonello; P Razzore; G Regolisti; C Scaroni; F Trepiccione; A Lenzi; A Peri Journal: J Endocrinol Invest Date: 2017-11-20 Impact factor: 4.256
Authors: M J E Dekker; D Marcelli; B Canaud; C J A M Konings; K M Leunissen; N W Levin; P Carioni; V Maheshwari; J G Raimann; F M van der Sande; L A Usvyat; P Kotanko; J P Kooman Journal: Eur J Clin Nutr Date: 2016-04-20 Impact factor: 4.016
Authors: Connie M Rhee; Vanessa A Ravel; Juan Carlos Ayus; John J Sim; Elani Streja; Rajnish Mehrotra; Alpesh N Amin; Danh V Nguyen; Steven M Brunelli; Csaba P Kovesdy; Kamyar Kalantar-Zadeh Journal: Nephrol Dial Transplant Date: 2015-09-25 Impact factor: 5.992
Authors: Vanessa A Ravel; Elani Streja; Rajnish Mehrotra; John J Sim; Kevin Harley; Juan Carlos Ayus; Alpesh N Amin; Steven M Brunelli; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Connie M Rhee Journal: Nephrol Dial Transplant Date: 2017-07-01 Impact factor: 5.992
Authors: Sunil V Badve; Lei Zhang; Jeff S Coombes; Elaine M Pascoe; Alan Cass; Philip Clarke; Paolo Ferrari; Stephen P McDonald; Alicia T Morrish; Eugenie Pedagogos; Vlado Perkovic; Donna Reidlinger; Anish Scaria; Rowan Walker; Liza A Vergara; Carmel M Hawley; David W Johnson Journal: Can J Kidney Health Dis Date: 2015-08-18